A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting

Conditions:   Lymphoma, Non-Hodgkin;   Lymphoma;   Lymphoma, B-Cell;   Lymphoma, Large B-Cell, Diffuse;   Neoplasms;   Neoplasms by Histologic Type;   Lymphoproliferative Disorders;   Lymphatic Diseases;   Immunoproliferative Disorders;   Immune System Disorder Intervention:   Biological: lisocabtagene maraleucel Sponsors:   Juno Therapeutics, Inc.;   Celgene Corporation Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials